EMA invites comments on consultation process for drug/device products
This article was originally published in Clinica
Executive Summary
The European Medicines Agency has launched for comment a 16-page draft guidance on how notified bodies consult the agency on products that combine devices with "an ancillary medicinal substance or an ancillary human blood derivate".